Mao J et al. |
Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. |
2017 |
Drug Metab. Rev. |
pmid:27718639
|
Josephson F et al. |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. |
2008 |
Eur. J. Clin. Pharmacol. |
pmid:18458892
|
Dutreix C et al. |
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. |
2014 |
Eur. J. Clin. Pharmacol. |
pmid:24839948
|
Nylén H et al. |
Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. |
2011 |
Eur. J. Clin. Pharmacol. |
pmid:21246351
|
Hole K et al. |
Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. |
2017 |
Eur. J. Clin. Pharmacol. |
pmid:27975131
|
Lütjohann D et al. |
4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. |
2009 |
Int J Clin Pharmacol Ther |
pmid:19954708
|
Pataj Z et al. |
Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. |
2016 |
J Chromatogr A |
pmid:26607314
|
Yang Z and Rodrigues AD |
Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? |
2010 |
J Clin Pharmacol |
pmid:20197489
|
Xu Y et al. |
LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. |
2013 |
J Pharm Biomed Anal |
pmid:23948760
|
van de Merbel NC et al. |
A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. |
2011 |
J Pharm Biomed Anal |
pmid:21507593
|
Ngaimisi E et al. |
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. |
2014 |
J. Antimicrob. Chemother. |
pmid:25096076
|
Bodin K et al. |
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. |
2001 |
J. Biol. Chem. |
pmid:11514559
|
Bodin K et al. |
Metabolism of 4 beta -hydroxycholesterol in humans. |
2002 |
J. Biol. Chem. |
pmid:12077124
|
Hasan M et al. |
Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. |
2016 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:27565568
|
Suzuki Y et al. |
Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. |
2013 |
J. Lipid Res. |
pmid:23833241
|
Honda A et al. |
Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. |
2009 |
J. Lipid Res. |
pmid:18815436
|
Breuer O |
Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma. |
1995 |
J. Lipid Res. |
pmid:8656065
|
Mao J et al. |
Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. |
2017 |
Pharm. Res. |
pmid:28815392
|
Diczfalusy U et al. |
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. |
2008 |
Pharmacogenet. Genomics |
pmid:18300941
|
Niemi M et al. |
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. |
2006 |
Pharmacogenet. Genomics |
pmid:16847425
|